XORTX Announces $3 Mln Private Placement To Advance Gout And Kidney Disease Program
(RTTNews) - XORTX Therapeutics Inc. (XRTX), a late-stage clinical pharmaceutical firm focused on therapies for progressive kidney disease and gout, has launched a non-brokered private placement to raise up to USD 3 million.
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief
